# $abvc

PDS Biotechnology's stock is experiencing a significant surge following the announcement of an extended global patent for its PDS0101 drug. This development, coupled with ongoing Phase [--] trials, is driving strong positive sentiment among investors and social media.

### About $abvc
PDS Biotechnology is a clinical-stage biopharmaceutical company focused on developing targeted cancer immunotherapies.  

### Top $abvc Social Posts
Top posts by engagements in the last [--] hours

*Showing a maximum of [--] top social posts without a LunarCrush subscription.*

"SENDAAA $TXG $ATNF $ME $TSVT $FDMT $SXTP $ETNB $AADI $AARD $ABCL $ABEO $ABSI $ABVC $ACIU $AXDX $SLRN $ACHV $ACHL $ACRS $ACRV $ACTU $ABOS $ACXP $ADAG $ACET $ADTX $ANL $ADVM $AVTE $AFMD $AGEN $AIMD $AKTX $AKBA $AKYA $TCRT $ALDX PHASE [--] + COMPOSITION PATENT = $PDSB POWER MOVE PDS Biotechnology recently secured a new composition-of-matter patent in Japan for PDS0101 extending global IP protection into the 2040s. 🌍 ✅ Broad composition + methods-of-use claims ✅ Patents already granted in US China https://t.co/FP6VvnGNSK PHASE [--] + COMPOSITION PATENT = $PDSB POWER MOVE PDS Biotechnology recently"  
[X Link](https://x.com/BuyTheUgly/status/2011960037061591424) [@BuyTheUgly](/creator/x/BuyTheUgly) 2026-01-16T00:33Z [--] followers, [---] engagements

Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing